[go: up one dir, main page]

DE60313434D1 - Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen - Google Patents

Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen

Info

Publication number
DE60313434D1
DE60313434D1 DE60313434T DE60313434T DE60313434D1 DE 60313434 D1 DE60313434 D1 DE 60313434D1 DE 60313434 T DE60313434 T DE 60313434T DE 60313434 T DE60313434 T DE 60313434T DE 60313434 D1 DE60313434 D1 DE 60313434D1
Authority
DE
Germany
Prior art keywords
combination
relates
treating hyperproliferative
compositions
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60313434T
Other languages
English (en)
Other versions
DE60313434T2 (de
Inventor
Charles Dean Stiles
Carlos Garcia-Echeverria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of DE60313434D1 publication Critical patent/DE60313434D1/de
Publication of DE60313434T2 publication Critical patent/DE60313434T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60313434T 2002-02-14 2003-02-14 Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen Expired - Lifetime DE60313434T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35691202P 2002-02-14 2002-02-14
US356912P 2002-02-14
PCT/EP2003/001507 WO2003068265A1 (en) 2002-02-14 2003-02-14 Methods and compositions for treating hyperproliferative conditions

Publications (2)

Publication Number Publication Date
DE60313434D1 true DE60313434D1 (de) 2007-06-06
DE60313434T2 DE60313434T2 (de) 2008-01-10

Family

ID=27734705

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60313434T Expired - Lifetime DE60313434T2 (de) 2002-02-14 2003-02-14 Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen

Country Status (11)

Country Link
EP (1) EP1476192B1 (de)
JP (1) JP5053503B2 (de)
CN (1) CN100591355C (de)
AT (1) ATE360442T1 (de)
AU (1) AU2003205768A1 (de)
BR (1) BR0307629A (de)
CA (1) CA2476000A1 (de)
DE (1) DE60313434T2 (de)
ES (1) ES2283744T3 (de)
PT (1) PT1476192E (de)
WO (1) WO2003068265A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
JP2007523956A (ja) * 2004-02-25 2007-08-23 ダナ−ファーバー キャンサー インスティテュート インク． 腫瘍細胞増殖を阻害するための方法
CN102924458B (zh) 2004-04-02 2014-11-05 Osi制药有限责任公司 6,6-双环取代的杂双环蛋白激酶抑制剂
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
ATE533057T1 (de) 2005-09-20 2011-11-15 Osi Pharm Inc Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401613A2 (de) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
EP2542893A2 (de) 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
JP2013527748A (ja) 2010-03-03 2013-07-04 オーエスアイ・ファーマシューティカルズ，エルエルシー インスリン様増殖因子１受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー
JP2013522215A (ja) 2010-03-09 2013-06-13 オーエスアイ・ファーマシューティカルズ，エルエルシー 組合わせ抗癌療法
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
WO2015035410A1 (en) 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
DE4129533A1 (de) * 1991-09-05 1993-03-11 Max Planck Gesellschaft Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
CN1117097C (zh) * 1998-05-29 2003-08-06 北京金赛狮生物制药技术开发有限责任公司 类胰岛素生长因子受体基因的反义核酸的抑癌作用

Also Published As

Publication number Publication date
EP1476192A1 (de) 2004-11-17
CN100591355C (zh) 2010-02-24
JP2005517040A (ja) 2005-06-09
ATE360442T1 (de) 2007-05-15
BR0307629A (pt) 2005-01-11
EP1476192B1 (de) 2007-04-25
WO2003068265A1 (en) 2003-08-21
AU2003205768A1 (en) 2003-09-04
JP5053503B2 (ja) 2012-10-17
ES2283744T3 (es) 2007-11-01
DE60313434T2 (de) 2008-01-10
PT1476192E (pt) 2007-07-26
CA2476000A1 (en) 2003-08-21
CN1630534A (zh) 2005-06-22

Similar Documents

Publication Publication Date Title
DE60313434D1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
ATE489955T1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE602004013971D1 (de) Marknagel zur Behandlung von proximalen Oberschenkelknochenbrüchen
EP1701664A4 (de) System und verfahren zur behandlung von gewebe
EP1626730A4 (de) Verfahren, gerät und zusammensetzung zur behandlung von akne
DE50312145D1 (de) Vorrichtung zur behandlung von frakturen des femur
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
AR023130A1 (es) Composiciones para promover el crecimiento
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE60118889D1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
ATE415163T1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
EP1506001A4 (de) Verfahren und zusammensetzungen zur behandlung von epithelläsionen in vagina, zervix und uterus
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
DE60327856D1 (de) Zusammensetzungen und verfahren zur hautbräunung
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
ATA20122001A (de) Verfahren zur behandlung von cellulosischen formkörpern
DE602004011275D1 (de) Zusammensetzungen und Verfahren zur Behandlung von Fettleibigkeit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN